TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04741997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Encorafenib Pill
Description: Encorafenib 450 mg will be administered orally once per day in continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Binimetinib Pill
Description: Binimetinib 45 mg will be administered orally twice per day in continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a dose of 480 mg IV infusion over 30 minutes every 4 weeks.
Study: NCT06382805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
Study: NCT06501339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance ECT
Description: Frequency of weekly sessions for 1 month, then fortnightly for 5 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet
Description: Aripiprazole 10 mg in the morning throughout the study period
Study: NCT05966727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine Powder
Description: Bile salt chelating resin, used as a lipid-lowering treatment.
Study: NCT06548113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: transcranial magnetic brain stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: transcranial magnetic brain stimulation
Study: NCT06382805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program
Description: The physiotherapy program will consist of cold-pack, US, transcutaneous electrical stimulation (TENS) and home exercise program. Cold-pack will be applied for 15 minutes. Continuous ultrasound will be applied on lateral epicondylitis with a 5-cm ultrasound head at a dose of 1.5W/cm2 for 5 minutes and a frequency of 1-MHZ. TENS application will be performed with the BTL 4000 combination device. TENS will be applied for 20 minutes, increasing the intensity of the current until the patient feels it. The treatment program will last for a total of two weeks, 5 days a week.
Study: NCT05560880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Gait training
Description: Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.
Study: NCT06382805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: The longitudinal muscle technique will be applied from the origin to the insertion of the forearm extensor muscles by a researcher with a Kinesio tape application certificate. In addition, transverse kinesio tape will be applied on the elbow using the fascia correction technique. The treatment program will last for a total of two weeks, 5 days a week.
Study: NCT05560880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Interval gait training
Description: subjects will walk for 20 minutes at theri best comfortable pace
Study: NCT06347978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Subjects will be randomized to either ON-OFF (Stimulation-Sham) or OFF-ON (Sham-Stimulation) arms. Patients in the ON-OFF arm will first be treated for up to 12 weeks with the parameters identified during the DBS optimization phase until the washout period. Patients in the OFF-ON will have their devices turned off and will not have their device switched on (activated) until the crossover point.~After completion of the first phase of the trial, patients will undergo another washout phase until they are within 20% of their pre-treatment Y-BOCS II score or 4 weeks have passed, whichever comes first. The purpose of the washout is to eliminate any residual effect of stimulation in the ON group.~Patients will then be advanced to the crossover phase. The participants who were initially randomized to the ON-OFF arm will be moved onto the sham (OFF) period, and the participants who were initially randomized to the OFF-ON group will be moved onto stimulation (ON) period for up to 12 weeks.
Study: NCT06382805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser therapy
Description: High intensity laser applications will be performed using the BTL-6000 (BTL Company, UK) device. The first 5 sessions will be applied to the painful area for 75 seconds at a dose of 4W 6 J/cm2 (analgesic effect) by making circular movements from the center to the outside. The remaining 5 sessions will be applied to the painful area with linear movements for 12 minutes and 30 seconds at a dose of 6W 100-150 J/cm2 (biostimulation effect). The treatment program will last for a total of two weeks, 5 days a week.
Study: NCT05683392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 insulin pump with Control-IQ technology 2.0
Description: t:slim X2 insulin pump with Control-IQ technology 2.0, and wearing the Dexcom G6 sensor.
Study: NCT05783349

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Unique blod sample
Description: sampling of 4mL of blood on lithium heparin tube, the day of frozen embryo implantation
Study: NCT05428007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Injectable solutions of sarilumab are formulated in 2 mL of aqueous solution in a 5 mL vial containing 175 mg/ml of sarilumab arginine (8.94 mg), histidine (3.71 mg), polysorbate 20 (2.28 mg), sucrose (57 mg) and Water for Injection USP.Patients will be administered sarilumab at a dose of 150 mg subcutaneously in combination with ipilimumab, nivolumab and relatlimab given intravenously, with nivolumab/relatlimab given intravenously, or sarilumab at a dose of 150 mg subcutaneously given alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection
Description: Ipilimumab injection is a sterile, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution, single-use, preservative-free, isotonic aqueous solution that may contain particles. It is formulated at a concentration of 5 mg/mL ipilimumab in TRIS hydrochloride (also known as 2-amino-2-hydroxymethyl-1,3-propanediol hydrochloride), sodium chloride, mannitol, pentetic acid (also known as diethylenetriaminepentaacetic acid or DTPA), polysorbate 80, and water at pH 7.0. Sodium hydroxide and/or hydrochloric acid may be used to adjust the pH of the solution. Ipilimumab Injection 200 mg/40 mL (5 mg/mL) is packaged in a 50-cc Type I flint molded glass vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Relatlimab
Description: The FDC drug product, referred to as nivolumab/relatlimab, contains relatlimab and nivolumab in a single vial in a kit of 2 vials. The product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution for IV infusion. It is formulated at a total protein concentration of 16 mg/mL (4 mg/mL relatlimab and 12 mg/mL nivolumab) and is packaged in a 20-cc glass vial in a kit of two vials. Each vial contains 80 mg of relatlimab and 240 mg of nivolumab.
Study: NCT05323734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxalone
Description: GNX will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT05069740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate Pill
Description: Salsalate acts as an NFkB inhibitor to reduce systemic inflammation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for the salsalate intervention
Study: NCT05024214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib + Envafolimab
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 28-day treatment cycle.~Envafolimab, 400 mg per dose, subcutaneous injection, dosed on D1 and then D15 of Treatment Cycle 1, and D1 of Treatment Cycle 2 and every subsequent cycles, with every 28 days as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered with water orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 42-day treatment cycle.
Study: NCT05289908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (1)
Description: Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (2)
Description: The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
Study: NCT04725071

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Impact Advanced Recovery
Description: L-arginine and omega-3 rich supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Boost High Protein
Description: conventional supplement
Study: NCT05795764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Response Planning
Description: Crisis Response Planning (CRP) is a brief psychotherapeutic intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard care provided for patients at risk for suicide
Study: NCT06440538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCMS + Contralateral Motor Training
Description: PCMS + Contralateral Motor Training will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2 Hz) to the weaker first dorsal interosseous (FDI) muscle immediately before a session of ballistic index finger abduction training at the opposite, stronger FDI muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCMS + Rest
Description: PCMS + Rest will involve delivering 360 pairs of TMS-PNS pulses (30min, 0.2Hz) to the weaker FDI followed by a 30-min rest.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PCMS + Contralateral Motor Training
Description: 360 TMS pulses will be delivered at a location 10-cm posterior to the participant's head (into the air, 0.2Hz) and no PNS pulses will be generated, followed by a session of 30-min ballistic index finger abduction training at the opposite, stronger FDI muscle.
Study: NCT06274905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: EMLA cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Ethyl chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqueous cream BP
Description: Aqueous cream
Study: NCT05266274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD47 monoclonal antibody
Description: patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation
Study: NCT04222504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of sexual health preventative services in the salon setting
Description: Participants at intervention salons will be offered a choice of receiving daily PrEP and/or contraceptives (oral and injectables). Participants that elect to receive at least PrEP or contraceptives will also be offered STI testing.~Follow-up visits will be planned for 3, 6, 9, and 12-months. Attendance at follow-up visits for monitoring and medication refill will be encouraged using text message reminders, WhatsApp support groups, and lottery-based incentives for free salon services.
Study: NCT05544396

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: probiotic
Description: probiotic group give probiotics (2 packs per day) for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic
Description: probiotic group give probiotics (2 packs per day) for 6 months.
Study: NCT05890755

Intervention type: OTHER
Intervention: Mechanical pertubation
Description: Acceleration or deacceleration of one treadmill gait belt.

Intervention type: OTHER
Intervention: Mechanical pertubation
Description: Acceleration or deacceleration of one treadmill gait belt.
Study: NCT05360602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid plus the standard care for post-PCI MI
Description: Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The standard care for post-PCI MI
Description: will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study: NCT05592522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External oblique intercostal block
Description: EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oblique subcostal TAP block
Description: OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Rectus sheath block
Description: Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Rectus sheath block
Description: Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
Study: NCT05105022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous induction of general anesthesia in infants 3 months or less.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous induction of general anesthesia in infants 3 months or less.
Study: NCT06048614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Enema (SE)
Description: infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin Suppository
Description: Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.